Abeona Therapeutics updated its investor presentation for use at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. Investors receive the materials Abeona expects to use at the conference, including the presentation dated for the event and identified under Regulation FD.

Key Highlights

  • Abeona Therapeutics’ disclosure is made under Regulation FD.
  • Chief Financial Officer Joseph Vazzano signed on behalf of Abeona Therapeutics on September 15, 2026.
  • Abeona Therapeutics prepared an updated presentation for the Wainwright Conference.

The materials are intended for use either in full or in part during the event.

Updated Presentation Prepared for Wainwright Conference

Abeona Therapeutics is furnishing the materials under Regulation FD. Joseph Vazzano, Abeona Therapeutics’ chief financial officer, signed the disclosure on behalf of the company on September 15, 2026. The disclosure also identifies Abeona Therapeutics Inc. (NASDAQ: ABEO) as the registrant and cites the Securities Exchange Act of 1934 in its signature language.